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Abstract 1 
Background: Recurrence of adrenocortical carcinoma (ACC) even after complete (R0) resection 2 
occurs frequently.  3 
Objective: The aim of this study was to identify markers with prognostic value for patients in this 4 
clinical setting. 5 
Design, Setting, and Participants: From the German ACC registry 319 patients with ENSAT stage I-III 6 
were identified. As an independent validation cohort 250 patients from three European countries 7 
were included. 8 
Outcome Measurements and Statistical Analysis: Clinical, histological and immunohistochemical 9 
markers were correlated with recurrence-free (RFS) and overall survival (OS).  10 
Results and Limitation: While univariable analysis within the German cohort suggested several 11 
factors with potential prognostic power, upon multivariable adjustment only a few including age, 12 
tumor size, venous tumor thrombus (VTT), and the proliferation marker Ki67 retained significance. 13 
Among these Ki67 provided the single best prognostic value for RFS (HR for recurrence 1.042 per 1% 14 
increase; p<0.0001) and OS (HR for death 1.051; p<0.0001) which was confirmed in the validation 15 
cohort. Accordingly, clinical outcome differed significantly between patients with Ki67<10%, 10-19%, 16 
and ≥20% (for the German cohort: median RFS: 53.2 vs. 31.6 vs. 9.4 months; median OS: 180.5 vs. 17 
113.5 vs. 42.0 months). Using the combined cohort prognostic scores including tumor size, VTT, and 18 
Ki67 were established. Although these scores discriminated slightly better between subgroups, there 19 
was no clinically meaningful advantage in comparison to Ki67 alone.  20 
Conclusion: This largest study on prognostic markers in localized ACC identified Ki67 as the single 21 
most important factor predicting recurrence in patients following R0 resection. Thus, evaluation of 22 
Ki67 indices should be introduced as standard grading in all pathology reports of ACC patients. 23 
Introduction 24 
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Adrenocortical carcinoma (ACC) is a rare but aggressive tumor entity with overall poor prognosis(1-1 
4). Response to medical treatment is limited and only recently the first randomized trial in patients 2 
with advanced disease established doxorubicin, etoposide, cisplatin plus mitotane as first-line 3 
cytotoxic therapy(5). However, this trial also demonstrated the limitations of systemic treatment 4 
with a median overall survival of only 15 months highlighting the importance of early diagnosis and 5 
appropriate initial treatment. Although strategies of surgical resection such as open or laparoscopic 6 
approaches are controversial(6-8), surgery is the mainstay of initial ACC therapy and currently 7 
provides the only realistic chance for cure of the disease. However, even after complete resection 8 
patients with ACC remain at high risk for recurrence.  9 
As a response to this clinical challenge adjuvant treatment with mitotane is frequently 10 
recommended(2, 9). Although mitotane has shown significant efficacy in preventing recurrence in 11 
this setting(10), it has a wide range of side effects and impacts hormone (11-13) and drug(14) 12 
metabolism. An additional adjuvant measure is irradiation of the tumor bed, for which some(15, 16) 13 
but not all(17) studies have demonstrated efficacy in preventing local recurrence but not to prolong 14 
recurrence-free survival (RFS) or overall survival (OS). Thus, all current treatment concepts have the 15 
disadvantages of uncertain efficacy and significant toxicity. Therefore, it would be of major 16 
importance to limit these treatments to patients with high risk of recurrence which is highly variable 17 
in ACC patients(1, 18-21).  18 
While histopathological scores are in use to differentiate between benign and malignant adrenal 19 
neoplasms they have not been investigated for their prognostic value. Recently, a number of 20 
molecular markers have been identified that were correlated with clinical outcome(22) and even had 21 
predictive value for treatment response(23, 24). However, the majority of applied techniques require 22 
fresh frozen tumor material and none of these markers has been evaluated in a large patient cohort. 23 
Therefore, we set out to identify prognostic factors from routine diagnostic work-up to provide 24 
guidance for adjuvant therapy after radical resection. For this purpose we took advantage of large 25 
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cohorts of ACC patients with detailed clinical and histopathological annotations within the European 1 
network for the study of adrenal tumors (ENSAT).  2 
3 
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Patients and Methods 1 
Patient selection 2 
Patients diagnosed with ACC between 1979 and 2011 were identified from the German ACC 3 
registry that fulfilled the following inclusion criteria: histologically proven ACC, and 4 
localized disease (ENSAT stage I-III(18)) after R0 resection. Resection status was judged on 5 
the basis of surgical and pathology reports. Furthermore, a minimum follow-up of 12 months 6 
was mandatory unless death occurred earlier. Two third of tumor samples of the German 7 
cohort were reviewed by the national reference pathologist (W.S.). All items required to 8 
calculate the scores suggested by Weiss, van Slooten, and Hough as well as 9 
immunohistochemical staining for Mib1 (Ki67) were evaluated. Further clinical information 10 
included in the analysis are provided in Table 1+2. Mitotane therapy was defined as adjuvant 11 
therapy with mitotane within 3 months following surgery; hormone production was recorded 12 
as any biochemically proven adrenocortical hormone excess.  13 
As an independent validation cohort patients from three European countries were identified 14 
from the ENSAT ACC registry based on the same inclusion criteria as stated above. Within 15 
this cohort a subset of pre-defined clinical parameters such as age, sex, ENSAT stage (tumor 16 
size, lymph node status and VTT), endocrine activity of the tumor and adjuvant mitotane 17 
therapy as well as Ki67 were analyzed. 18 
Both registries had been approved by the local ethics committees of all partaking centers and all 19 
included patients had provided written informed consent. 20 
 21 
Outcome definitions and statistical analysis 22 
The pre-specified primary endpoint of the study was RFS, which was defined as the time interval 23 
between initial surgery and the date of radiologic evidence of disease relapse, death resulting from 24 
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any cause or the date of last follow-up. As a secondary endpoint OS was calculated from the date of 1 
first surgery to death from any cause or the last follow-up visit. RFS and OS rates over time from 2 
initial surgery were estimated using the Kaplan-Meier method. The significance of the demographic 3 
parameters and clinical characteristics for prognosis of RFS and OS was determined by univariable 4 
and multivariable Cox regression models. As the lowest category for Ki67 <5% and for tumor size 5 
<5cm was set.  6 
As for the diagnostic scores different strategies were applied to take into account limitations of 7 
individual residual analyses. Indeed, following an exploratory analysis model construction was based 8 
on stepwise, forward and backward selection using p-value criteria in the range between 0.05 and 9 
0.25. Tumor size was explored as a continuous factor and according to cut-off values. Potential cut-10 
off values for tumor size were pre-specified at 5cm, 8cm, 11cm, 15cm, and 20cm. Furthermore, the 11 
number of factors included, the score statistic, the contribution to the change of the hazard in the 12 
Cox-model as well as differentiation of survival curve estimation by use of the predictor were 13 
considered. Martingale residual analysis was performed indicating well fitting with continuous Ki67 14 
and exploring grouping by equidistant increases of 5% or of 10%. Extensive sensitivity analyses with 15 
multivariable models including, excluding and exchanging potential factors from the first explored 16 
models were performed. Comparisons between groups were conducted applying the log rank test 17 
and presenting two-sided p-values. Estimates of median times to event and hazard ratios (HR) are 18 
provided with 95% confidence intervals (CI).  19 
 20 
21 
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Results 1 
Patient cohorts and characteristics 2 
A total of 319 patients from the German registry and additional 250 patients from 7 European 3 
centers fulfilled the pre-specified inclusion criteria. Patient characteristics at initial diagnosis 4 
are summarized in Table 1. While tumor stage and most of other clinical items were not 5 
different between the groups, the percentage of patients on adjuvant mitotane treatment was 6 
significantly lower in the German cohort (26.3 vs. 64.8%).  7 
 8 
German cohort 9 
Univariable analyses for all presumably relevant demographic, clinical, and histopathological 10 
parameters were performed (Table 2). None of the clinical parameters showed significant correlation 11 
with both RFS and OS. Tumor stage was of prognostic value but the discrimination was not found to 12 
be sufficient for clinical guidance on adjuvant therapeutic strategies (Supplementary Figure 1). 13 
Within the large set of histological parameters only few were associated with poor clinical outcome 14 
(Table 2) and several multi-item scores were not able to predict outcome better than individual 15 
parameters. In contrast, the proliferation marker Ki67 was found to be the single most relevant 16 
predictor of disease recurrence and survival with an hazard ratio of 1.042 per 1% increase of Ki67 17 
index for recurrence (p<0.0001) and 1.051 for death (p<0.0001), respectively (Table 2). Along the 18 
same line, Ki67 indices of <10%, 10-19%, and ≥20% provided highly significant differences for both 19 
RFS (p<0.0001) and OS (p<0.0001) translating into a median RFS and a median OS of 53.2 [95% CI 20 
37.7; 74.7] and 180.5 [152.9; no upper limit] months for Ki67<10%, 31.6 [21.5; 48.0] and 113.5 [64.4; 21 
153.7] months for Ki67 10-19%, and 9.4 [7.3; 13.1] and 42.0 [33.7; 56.8] months for Ki67 ≥20%, 22 
respectively (Figure 1A+C).  23 
Upon a stepwise and a backward multivariable analysis involving all parameters with a p-value of 24 
<0.15 in the univariable analysis plus adjuvant mitotane therapy and taking into account sensitivity 25 
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analyses and regression diagnostics, Ki67 remained the factor with the best prognostic power with a 1 
hazard ratio of 1.046 per 1% for RFS and 1.061 per 1% for OS (Table 4). When Ki67 was used as a 2 
categorical variable the corresponding HR for RFS was 1.94 [1.25-3.03; p=0.0034] for Ki67≥10% and 3 
2.58 [1.71-3.92; p<0.0001] for Ki67≥20% and for OS 3.69 [1.75-7.77; p=0.0006] for Ki6710% and 4 
3.59 [1.99-6.48; p<0.0001] for Ki6720%. Notably, no other histological parameter retained its 5 
relevance when the analysis was adjusted for Ki67. While age, tumor size, and VTT had some 6 
association with clinical outcome none of these factors showed a similar prognostic power for both 7 
RFS and OS as Ki67.  8 
Of note, adjuvant treatment with mitotane was not significantly associated with clinical outcome in 9 
univariable analysis, but after multivariable adjustment a trend for longer RFS was detectable (HR 10 
0.71; p=0.087) and it became a significant factor for OS (HR 0.41; p=0.009, Table 4).  11 
 12 
European validation cohort 13 
Following these observations we investigated a defined sub-set of clinical and histopathological 14 
parameters within the European validation cohort. Comparable to the German cohort the 15 
proliferation marker Ki67 provided the best prognostic value for prediction of RFS and OS, 16 
respectively (Table 3 and Figure 1B+D). Following multivariable analysis Ki67 retained highly 17 
significant association with RFS and OS with a hazard ratio for recurrence of 1.020 [1.010-1.029] and 18 
for overall survival of 1.026 [1.013-1.039] per 1% increase, respectively (Table 4). Similar to the 19 
German cohort, age tumor size and the presence of VTT harbored none or only minor prognostic 20 
value (Table 4).  21 
 22 
Establishment of a prognostic score 23 
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In a next step, we aimed at the development of a prognostic score for further clinical guidance in the 1 
management of patients with ACC after complete resection. For this purpose, we applied two 2 
different models using the pooled data of both cohorts (n=569). Both algorithms included the 3 
following 3 risk factors (RF): Ki67, tumor size between 15 and 20 cm and presence of VTT.  4 
In the first, basic model Ki67 was regarded as one RF for Ki67≥10% and as a second RF for Ki67≥20%. 5 
Either tumor size of 15-20cm or presence of VTT was accounted as one combined RF. Each of these 3 6 
RF was counted as 1 point in the prognostic score, which resulted in 4 groups (0-3 RF) with different 7 
outcome. However, applying this score, estimated RFS and OS of the different risk groups by Kaplan-8 
Meier analysis provided no clinically meaningful separation between the two groups with the highest 9 
scores which were therefore combined (Figure 2B, Supplementary Figure 2B). In the next model the 10 
same RF were weighted individually according to their prognostic power and specifically for RFS. This 11 
second modeling resulted in a slightly improved risk prediction and allowed for differentiation in 12 
more subgroups (Figure 2C, Supplementary Figure 2C). 13 
14 
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Discussion 1 
This largest study on prognostic factors in localized ACC provides strong evidence that Ki67 index is 2 
the most powerful tool of all parameters analyzed in this study to predict recurrence in two 3 
independent cohorts of patients after complete surgical resection. Likewise, OS was also strongly 4 
associated with the Ki67 index. Following multivariable analysis including age, tumor stage, adjuvant 5 
mitotane treatment and all standard histological parameter used in ACC, the Ki67 index retained its 6 
outstanding prognostic power. Importantly, these results initially obtained from a German cohort 7 
could be validated in an independent European sample. In a next step, we aimed at the 8 
establishment of clinical risk scores. Although both applied models including the parameters Ki67, 9 
tumor size, and presence of VTT were able to discriminate patient cohorts with different clinical 10 
outcome, the added value of these scores in comparison to the use of Ki67 alone was modest. Thus, 11 
Ki67 is obviously the best factor to establish a grading system in ACC with Ki67 <10% defining grade 1 12 
tumors, Ki67 10-19% grade 2 and Ki67 ≥20% grade 3 tumors.  13 
 14 
ENSAT stage III has been defined by the presence of positive lymph nodes, tumor infiltration in 15 
surrounding tissue or the presence of VTT, while stage IV is restricted to patients with distant 16 
metastasis(18). This system which had been independently validated(25) performs well over the 17 
whole spectrum of ACC patients to predict overall prognosis. However, as we demonstrate herein 18 
within the pre-selected patient group with localized disease following complete surgical resection the 19 
ENSAT staging system seems to be of limited relevance. The reason for this lack of prognostic power 20 
is most likely due to the fact that stage III usually comes with a relatively high risk of incomplete 21 
resection. In fact, according to a German(26) and an U.S. series(20) this accounts for about 10% of 22 
patients with localized ACC. However, these cases as well as those with uncertain resection status 23 
were excluded from our analysis, because the high risk for recurrence in these patients is obvious.  24 
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Another initially surprising result is the fact that the outcome of patients with a tumor size >20 cm 1 
was better than of those with smaller tumors. However, as described above, this series is a highly 2 
selected cohort and very large tumors that are still resectable and not metastasized at the time of 3 
surgery might indeed represent a subgroup of tumors with specific biological behavior.  4 
To appreciate the quite variable outcome even in the well defined subgroup of completely resected 5 
patients, additional parameters with prognostic value need to be taken into consideration. Recently, 6 
inclusion of tumor grading on the basis of mitotic counts has been proposed to improve the 7 
prediction of prognosis(27). Accordingly, in our two independent cohorts, quantification of Ki67 as a 8 
well defined marker of cellular proliferation provided additional prognostic information with relevant 9 
clinical impact. This is in good agreement with earlier studies which had suggested Ki67 as a marker 10 
with prognostic value in ACC patients(28-31). While these series were small and the overall results 11 
therefore not consistent, based on the current results, we strongly suggest tumor grading based on 12 
three categories of a Ki67 index <10%, 10-19% and above 20%.  13 
 14 
Ki67 index in our analysis proved to be superior to different histological scores such as those 15 
proposed by Weiss, van Slooten or Hough that are currently in clinical use for the differential 16 
diagnosis of adrenal tumors. The reason for this finding probably relates to the fact that a number of 17 
sub-items required for these scores such as atypical mitoses, abnormal nucleoli and nuclear atypia 18 
had no prognostic potential or were even associated with a trend towards better outcome. This does 19 
not question the overall applicability of the scores to discern between benign adrenal adenomas and 20 
ACC for which purpose they had been originally proposed. However, the findings highlight the 21 
limitation of the scores as prognostic tools for this particular group of patients and fuels speculation 22 
whether these sub-items are of particular importance for the scores. Along the same line, some 23 
pathologists have argued for a simplified Weiss score that bases on the more reliable criteria only(32, 24 
33).  25 
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 1 
The effect of mitotane on clinical outcome was surprisingly different between the German cohort 2 
and the validation cohort. Due to the retrospective nature of our study we can only speculate about 3 
the underlying reasons for this difference. However, the fact that in the German series only 84 out of 4 
319 patients (26%) were treated with mitotane in comparison to 65% in the validation series already 5 
point towards a general difference in therapeutic policies. One explanation for this discrepancy is 6 
probably related to the time interval of patient inclusion. Two third of the German patients were 7 
diagnosed before 2007, when the land-mark study on the adjuvant usage of mitotane had been 8 
published(10), whereas the non-German cohorts were recruited mostly after that time period. 9 
However, this observation could also be interpreted as another hint that not all patients will benefit 10 
from mitotane treatment and prospective trials are required to provide reliable answers.  11 
 12 
In variance to recent studies in the current cohort no relevant adverse effect of steroid excess on RFS 13 
and OS was found. One of the differences that are present in the current publications refer to the 14 
cohorts. While in a recent manuscript by Berruti and colleagues (34) some overlap with our study is 15 
present adding patients from North America might have contributed to the observed differences. In 16 
fact, in two studies from single US centers (35, 36) both find Cushing’s syndrome as a marker of poor 17 
prognosis. In addition – and probably more importantly - while in our study hormone excess was 18 
defined by biochemical means, in the published studies this was judged on a clinical basis.  19 
 20 
Our study has obvious limitations as a result of its non-randomized design, in which multiple factors 21 
may have led to different treatment decisions in individual patients. These limitations are shared by 22 
other studies that have investigated prognostic factors in ACC patients (for details see Suppl. Table 23 
1). Furthermore, variability of Ki67 index evaluation at different clinical centers is to be expected. 24 
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This refers to pre-analytic variations, usage of different antibodies and staining reagents as well as 1 
quantification underestimating tumor heterogeneity.  2 
Despite these limitations the high number of patients as well as the inclusion of an independent 3 
validation cohort underscores the overall robustness of the reported findings. The results could have 4 
immediate impact on the clinical decision for or against adjuvant treatment options: even after 5 
complete resection patients with high Ki67 index have a high likelihood to suffer from recurrent 6 
disease, thereby calling for a more aggressive therapeutic course. In contrast, patients with a low 7 
Ki67 index are likely to have a less favorable risk/benefit ratio of adjuvant treatment considering its 8 
substantial toxicity. Whether or not mitotane is the appropriate treatment particularly for tumors 9 
with high proliferation rate remains open. At least part of this question will be answered by the 10 
ongoing ADIUVO trial (mitotane vs. observation in low grade tumors after R0 resection; www.adiuvo-11 
trial.org)  12 
 13 
Conclusions 14 
In conclusion, in this study analyzing multiple potential prognostic markers in two independent 15 
cohorts of 568 patients with completely resected ACC Ki67 emerged as the single most important 16 
factor predicting recurrence and should be part of any pathology report of ACC to provide tumor 17 
grade. This finding will further guide the management of patients with this rare disease. 18 
 19 
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Table 1: Baseline characteristics of the two patient cohorts 1 
 n German cohort 
(n=319) 
n Validation cohort 
(n=250) 
Age 319 46.3 (0.4-83.6) 250 46.7 (9.1-83.0) 
Sex  319 207 females, 112 males 250 162 females, 88 males 
Median tumor size (cm) 318 10.0 (2.3-40.0) 248 11.0 (2.0-30.0) 
ENSAT stage (18) 319 I: 27 (8.5%) 
II: 202 (63.3%) 
III: 90 (28.2%) 
245 I: 22 (9.0%) 
II: 156 (63.7%) 
III: 67 (27.3%) 
Median Ki67 index (%) 223 10 (1-60) 239 10 (0-82) 
Adjuvant mitotane therapy 319 84 (26.3%) 219 142 (64.8%) 
Adjuvant radiation 313 30 (9.6%) 250 7 (2.8%) 
History of recurrence 319 206 (64.6%) 250 135 (78.4%) 
Median follow-up of alive 
patients (months) 
205 43.7 162 69.8 
Death from any cause 319 114 (35.7%) 250 88 (35.2%) 
Death from ACC 319 100 (31.3%) 250 65 (26.0%) 
 2 
 3 
Beuschlein et al. Prognostic markers for completely resected adrenocortical cancer 19 
Table 2: Univariable analysis (Cox regression) of the German cohort (n=319) 1 
   RFS 
 
OS 
Factor [unit] N of 
319 
N+ events hazard ratio p-value events hazard ratio p-value 
Age [years] 319  218 1.010 per year 0.0132 114 1.008 per year 0.1330 
Tumor size [cm] 
 ≥5 
 ≥8 
 ≥11 
 ≥15 
 ≥20 
318 
  
 
293 
234 
151 
68 
18 
218  
1.276 
1.590 
1.377 
1.477 
0.819 
 
0.3366
0.0047 
0.0189 
0.0150 
0.5217 
114  
1.550 
1.270 
1.153 
1.491 
0.595 
 
0.2332 
0.2853 
0.4493 
0.0652 
0.3087 
Tumor size 8-20 cm 318 216 218 1.589 0.0025 114 1.381 0.1296 
Tumor size 11-20 cm 318 133 218 1.450 0.0066 114 1.268 0.2081 
Tumor size 15-20cm 318 50 218 1.777 0.0009 114 1.900 0.0048 
Infiltration in surrounding 
tissue 
266 58 179 1.236 0.2239 101 1.468 0.0823 
Invasion in adjacent organ 271 11 183 1.601 0.0080 105 1.289 0.5838 
Lymph node positivity 250 20 171 2.173 0.0020 97 1.846 0.0569 
Presence of venous tumor 306 25 210 1.441 0.1215 112 1.742 0.0409 
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thrombus in renal vein or 
vena cava  
ENSAT stage 
 II 
 II or III 
319  218  
1.257 
1.780 
 
0.3885 
0.0373 
114  
1.290 
2.155 
 
0.5002 
0.0449 
Glucocorticoid secretion 184 101 125 1.115 0.5512 65 0.715 0.1889 
Adjuvant mitotane 319 84 218 0.855 0.3402 114 0.650 0.1038 
Ki67 [%] 
 ≥5 
 ≥10 
 ≥15 
 ≥20 
 ≥25 
223  
184 
139 
82 
69 
37 
122  
2.616 
2.743 
2.810 
3.526 
3.050 
 
0.0002 
<0.0001 
<0.0001 
<0.0001 
<0.0001 
69  
4.417 
5.322 
4.955 
5.595 
4.320 
 
0.0015 
<0.0001 
<0.0001 
<0.0001 
<0.0001 
Ki67 [%] 223  143 1.042 per 1% <0.0001 69 1.051 per 1% <0.0001 
Weiss Score ≥5
#
 199 143 138 1.435 0.0638 70 1.155 0.5810 
Mitotic count >5/50HPF 220 154 149 1.647 0.0088 77 1.357 0.2410 
Nuclear atypia 238 193 162 0.675 0.0461 86 0.703 0.1877 
Atypical mitoses 227 60 154 0.927 0.6819 80 0.897 0.6760 
Clear cells <25 % 201 183 139 2.825 0.0049 70 1.650 0.2822 
Diffuse architecture 209 169 141 1.648 0.0297 73 0.834 0.5157 
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Venous invasion 213 91 147 1.758 0.0007 75 1.669 0.0286 
Sinusoidal invasion 210 123 146 1.271 0.1594 74 0.988 0.9574 
Capsular invasion 271 142 182 1.343 0.0489 99 1.252 0.2694 
Necrosis 234 189 159 1.633 0.0226 83 1.830 0.0626 
Hough score≥3.23
#
 189 96 134 1.390 0.0001 68 1.065 0.5869 
Vascular invasion 273 176 187 1.462 0.0152 98 1.297 0.2289 
Fibrous bands 204 121 140 1.270 0.1696 69 1.275 0.372 
van Slooten score
#
 189 96 134 1.027 0.0576 68 1.002 0.9181 
Mitotic count >2/10HPF  220 110 149 1.828 0.0003 77 1.383 0.1603 
Nuclear hyperchromasia 231 157 159 0.876 0.4347 83 0.820 0.3891 
Abnormal nucleoli 223 92 155 0.804 0.1803 81 0.980 0.9275 
 1 
# 
the cutoff for these scores were set as the median.  2 
N+, number of patients that fulfilled the given criterion.  3 
4 
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Table 3: Univariable analysis (Cox regression) of the validation cohort (n=250) 1 
 RFS 
 
OS 
Factor [unit] N of 
250 
N 
+ 
events hazard ratio p-value N of 250 N 
+ 
events hazard ratio p-value 
Age [years] 247  145 1.007 per year 0.2917 249  87 0.996 per year 0.6151 
Tumor size [cm] 
 ≥5 
 ≥8 
 ≥11 
 ≥15 
 ≥20 
245  
230 
195 
131 
64 
21 
144  
1.344 
2.034 
1.772 
1.245 
0.984 
 
0.4803 
0.0051 
0.0012 
0.2268 
0.9540 
247 
 
 
232 
197 
133 
66 
23 
86  
0.576 
1.305 
1.408 
1.344 
0.849 
 
0.2348 
0.3790 
0.1287 
0.1907 
0.6426 
Tumor size 8-20 cm 245 174 144 1.658 0.0111 247 174 86 1.302 0.2863 
Tumor size 11-20 cm 245 110 144 1.760 0.0008 247 110 86 1.483 0.0690 
Tumor size 15-20cm 245 43 144 1.361 0.1356 247 43 86 1.621 0.0512 
Infiltration in surrounding 
tissue 
195 41 124 1.100 0.6534 195 41 69 0.982 0.9500 
Lymph node positivity 164 9 100 1.060 0.8923 164 9 54 2.027 0.1058 
Presence of venous tumor 
thrombus in renal vein or 
195 23 124 2.207 0.0012 195 23 69 2.024 0.0237 
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vena cava 
ENSAT stage 
 II 
 II or III 
242  141  
1.342 
2.675 
 
0.4291 
0.0099 
244  84  
0.540 
1.389 
 
0.1356 
0.4268 
Ki67 [%] 
 ≥5 
 ≥10 
 ≥15 
 ≥20 
 ≥25 
236  
151 
126 
88 
74 
47 
137  
2.715 
2.734 
3.015 
2.751 
2.667 
 
<0.0001 
<0.0001 
<0.0001 
<0.0001 
<0.0001 
238  
151 
126 
88 
74 
47 
84  
1.925 
2.164 
2.835 
2.866 
2.355 
 
0.0070 
0.0009 
<0.0001 
<0.0001 
0.0005 
Ki67 [%] 236  137 1.024 per 1% <0.0001 238  84 1.023 per 1% <0.0001 
adjuvant mitotane 218 142 133 1.095 0.6209 218 142 77 1.054 0.8226 
 1 
N+, number of patients that fulfilled the given criterion.  2 
 3 
4 
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Table 4: Multivariable analysis (Cox regression) of the most relevant factors for recurrence-free and overall survival* 1 
 Recurrence-free survival 
 
 
 German cohort  Validation cohort 
Factor [unit] N+ hazard ratio 95% CI p-value  N+ hazard ratio 95% CI p-value 
Age [years]  1.013  1.004-1.022 0.0054   1.001 0.986-1.016 0.8961 
Tumor size 15 – 20 cm 34 1.601 1.033-2.480 0.0354  38 1.369 0.876-2.138 0.1678 
Presence of venous 
tumor thrombus in 
renal vein or vena cava 
15 1.327 0.724-2.432 0.3599  23 1.828 1.111-3.008 0.0176 
Ki67 [%]  1.046 1.033-1.059 <0.0001   1.020 1.010-1.029 <0.0001 
Adjuvant mitotane 63 0.705 0.473-1.052 0.0867  117 0.966 0.654-1.426 0.817 
 
 
 
Overall survival 
 
 
 German cohort  Validation cohort 
Factor [unit] N+ hazard ratio 95% CI p-value  N+ hazard ratio 95% CI p-value 
Age [years]  1.014 1.001-1.028 0.0314   0.990 0.970-1.010 0.3325 
Tumor size 15 – 20 cm 34 1.192 0.632-2.,251 0.5872  38 1.830 1.070-3.128 0.0273 
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Presence of venous 
tumor thrombus in 
renal vein or vena cava 
15 2.141 1.075-4.265 0.0303  23 1.438 0.762-2.712 0.2622 
Ki67 [%]  1.061 1.044-1.079 <0.0001   1.026 1.013-1.039 <0.0001 
Adjuvant mitotane 63 0.410 0.211-0.797 0.0086  117 0.804 0.482-1.343 0.4053 
 1 
* the analyses include only patients for whom all parameters were available (n=214 for the German cohort, of whom 139 experienced recurrence and 114 died 2 
and n= 181 with 114 recurrences and 65 deaths for the validation cohort) 3 
N+, number of patients that fulfilled the given criterion.  4 
  5 
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Supplemental Table 1: Overview on recently published cohorts of patients with adrenal cancer  1 
 2 
Study Cohort 
size 
Description Remarks 
Terzolo 2007 (10) 177 Patients after radical surgery 
with or without adjuvant 
mitotane therapy 
Partial overlap of patient cohorts. 
Study includes patients also with 
uncertain restriction status  
Berruti 2014 (34) 524 Patients after R0 resection 
investigated for the prognostic 
value of clinically overt 
Cushing’s syndrome for OS and 
RFS 
Partial overlap of patient cohorts. 
Study with the primary aim to 
assess cortisol excess as a 
prognostic factor 
Else 2014 (36) 391 Prognostic value present for 
cortisol excess, tumor stage, 
tumor grade (on the basis of 
mitotic count lower/higher 20 per 
50 HPF) 
No overlap of patient cohorts. 
Cohort including patients of all 
stages irrespective of resection 
status 
Ayala-Ramirez 
2014 (35) 
330 Prognostic value for RFS present 
for surgical margins, and disease 
stage 
No overlap of patient cohorts. 
Cohort including patients of all 
stages irrespective of resection 
status 
 3 
 4 
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Figure 1: Kaplan-Meier analysis of Ki67 index on recurrence free survival (A+B) and overall survival 1 
(C+D) of the German cohort (A+C) and the validation cohort (B+D), respectively. 2 
 3 
 4 
 5 
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Figure 2: Kaplan-Meier analyses for recurrence free survival on the complete cohort with Ki67 only (≥10% and ≥20%, A), and based on a basic risk score (Ki67 1 
10-20%, 1 point; Ki67 >20%, 2 points; tumor size 15-20 cm or presence of venous tumor thrombus, 1 point, B), and weighted risk score (Ki67 per 1%, presence 2 
of venous tumor thrombus or tumor size 15-20cm, C), respectively. 3 
 4 
 5 
 6 
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Supplemental Figure 1: Kaplan-Meier analysis of ENSAT stage on recurrence free survival (A+B) and 1 
overall survival (C+D) for the German (A+C) and the validation cohort (B+D), respectively.  2 
 3 
 4 
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Supplemental Figure 2: Kaplan-Meier analyses for overall survival on the complete cohort with Ki67 only (≥10% and ≥20%, A), and based on a basic risk score 1 
(Ki67 10-20%, 1 point; Ki67 >20%, 2 points; tumor size 15-20 cm or presence of venous tumor thrombus, 1 point, B) and weighted risk score (Ki67≥10%, 2 
Ki67≥20%, presence of venous tumor thrombus or tumor size 15-20cm, C), respectively. 3 
 4 
 5 
 6 
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